Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Growth Metrics

Cresco Labs (CRLBF) Notes Payables (2022 - 2025)

Cresco Labs filings provide 4 years of Notes Payables readings, the most recent being $10.8 million for Q4 2025.

On a quarterly basis, Notes Payables changed N/A to $10.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.8 million, a N/A change, with the full-year FY2025 number at $10.8 million, changed N/A from a year prior.
Notes Payables hit $10.8 million in Q4 2025 for Cresco Labs, down from $22.3 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $29.2 million in Q1 2022 to a low of $10.8 million in Q4 2025.
Median Notes Payables over the past 4 years was $20.5 million (2022), compared with a mean of $19.5 million.